387 related articles for article (PubMed ID: 29554497)
1. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
Papakostas GI; Nielsen RZ; Dragheim M; Tonnoir B
J Psychiatr Res; 2018 Jun; 101():72-79. PubMed ID: 29554497
[TBL] [Abstract][Full Text] [Related]
2. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
[TBL] [Abstract][Full Text] [Related]
3. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
Llorca PM; Lançon C; Brignone M; Rive B; Salah S; Ereshefsky L; Francois C
Curr Med Res Opin; 2014 Dec; 30(12):2589-606. PubMed ID: 25249164
[TBL] [Abstract][Full Text] [Related]
4. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.
Thase ME; Danchenko N; Brignone M; Florea I; Diamand F; Jacobsen PL; Vieta E
Eur Neuropsychopharmacol; 2017 Aug; 27(8):773-781. PubMed ID: 28663124
[TBL] [Abstract][Full Text] [Related]
6. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
Wang G; Gislum M; Filippov G; Montgomery S
Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram.
Jacobsen PL; Nomikos GG; Zhong W; Cutler AJ; Affinito J; Clayton A
CNS Spectr; 2020 Feb; 25(1):50-63. PubMed ID: 31010445
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.
Fagiolini A; Florea I; Loft H; Christensen MC
J Affect Disord; 2021 Mar; 283():472-479. PubMed ID: 33516560
[TBL] [Abstract][Full Text] [Related]
9. Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy: Results of the VIVRE Study.
McIntyre RS; Florea I; Pedersen MM; Christensen MC
J Clin Psychiatry; 2023 May; 84(4):. PubMed ID: 37227402
[No Abstract] [Full Text] [Related]
10. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control.
Kasper S; Corruble E; Hale A; Lemoine P; Montgomery SA; Quera-Salva MA
Int Clin Psychopharmacol; 2013 Jan; 28(1):12-9. PubMed ID: 23023074
[TBL] [Abstract][Full Text] [Related]
11. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder.
Brignone M; Diamand F; Painchault C; Takyar S
Curr Med Res Opin; 2016; 32(2):351-66. PubMed ID: 26637048
[TBL] [Abstract][Full Text] [Related]
13. Agomelatine versus other antidepressive agents for major depression.
Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
Cochrane Database Syst Rev; 2013 Dec; (12):CD008851. PubMed ID: 24343836
[TBL] [Abstract][Full Text] [Related]
14. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
15. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study.
Wang J; Liu XF; Feng C; Bao Q; Fu HR
Int J Psychiatry Clin Pract; 2019 Nov; 23(4):245-250. PubMed ID: 29113521
[No Abstract] [Full Text] [Related]
17. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
[TBL] [Abstract][Full Text] [Related]
18. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
Demyttenaere K; Corruble E; Hale A; Quera-Salva MA; Picarel-Blanchot F; Kasper S
CNS Spectr; 2013 Jun; 18(3):163-70. PubMed ID: 23472671
[TBL] [Abstract][Full Text] [Related]
19. The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine.
François C; Nielsen R; Danchenko N; Williams V; Lançon C
Curr Med Res Opin; 2017 Jun; 33(6):1057-1066. PubMed ID: 28277865
[TBL] [Abstract][Full Text] [Related]
20. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
Inoue T; Nishimura A; Sasai K; Kitagawa T
Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
